Close



Dec 14, 2021 09:06AM
May 7, 2021 09:20AM
Feb 14, 2019 07:00AM
Feb 12, 2019 06:00AM
Feb 7, 2019 04:15PM
Dec 10, 2018 09:28AM
Dec 6, 2018 07:15AM Axovant Sciences (AXON) Reports Feedback from FDA Meeting Regarding AXO-Lenti-PD; Announces Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial
Dec 6, 2018 07:00AM
Nov 26, 2018 08:00AM
Jul 12, 2018 07:32AM
Jun 11, 2018 09:16AM
Jan 9, 2018 07:00AM
Jan 9, 2018 07:00AM
Jan 8, 2018 07:41AM Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
Jan 8, 2018 07:01AM
Jan 8, 2018 07:00AM
Jan 8, 2018 07:00AM
Dec 21, 2017 09:24AM
Nov 2, 2017 04:30PM
Sep 26, 2017 09:30AM
Sep 26, 2017 07:02AM Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy Endpoints
Sep 26, 2017 07:00AM
Aug 7, 2017 07:00AM
Jun 19, 2017 07:01AM
Jun 19, 2017 07:00AM
Jun 13, 2017 07:00AM
Apr 11, 2017 09:29AM
Apr 10, 2017 09:25AM Pre-Open Movers 04/10: (STRP) (SWFT) (GERN) Higher; (OMED) (TXMD) (SNOW) Lower (more...)
Apr 10, 2017 08:16AM
Apr 10, 2017 08:15AM
Feb 14, 2017 04:15PM
Feb 13, 2017 07:03AM
Feb 13, 2017 07:00AM
Jan 12, 2017 07:00AM
Jan 9, 2017 07:00AM Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference

240,623 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All